Markets

GT Biopharma Announces IND Clearance From FDA For GTB-5550 In Multiple Myeloma

Sep 15, 2026 · 09:16 AM ET· updated 2h ago

FDA clearance of a new IND for GTB-5550 in multiple myeloma (MM) under an investigator sponsored trial (IST) protocolInitiation of Phase 1 trial in MM patients contingent upon timing and receipt of non-dilutive grant

Why It Matters

GT Biopharma got permission to test a new cancer medicine in patients. This is an early step that shows the company is moving forward with its research plan.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

GTBP9.33

-2.30 (-19.79%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.